According to the American skin cancer foundation, there are more new cases of skin cancer than the combined incidence of cancers of the breast, prostate, lung and colon each year and malignant melanoma represents its deadliest form. About 50% of all cases are characterized by a particular mutation BRAF V600E in the BRAF-gene. Recently developed highly specific drugs are able to fight BRAF V600E mutated tumors, but require diagnostic tools for fast and reliable mutation detection to warrant treatment efficiency. We completed a preliminary clinical trial applying cantilever array sensors to demonstrate identification of a BRAF V600E single-point mutation using total RNA obtained from biopsies of metastatic melanoma of diverse 2 sources (surgical material either frozen or fixated with formalin and embedded in paraffin). The method is faster than the standard Sanger or pyrosequencing methods and comparably sensitive as next-generation sequencing. Processing time from biopsy to diagnosis is below one day and does not require PCR-amplification, sequencing and labels.Cancer is the number one cause of death worldwide surpassing cardiovascular disease or all strokes 1 . The most common malignancy in humans is skin cancer 2 . The occurrence of cutaneous malignant melanoma has steadily increased over the past 50 years in fair-skinned populations and still grows in many developed countries as a result of changing sun-seeking behavior. Only up to 5% of all skin cancers are malignant melanomas, but are responsible for almost all fatalities. However, recently novel treatment methods have been developed. They are based on compounds with high specificity that have initiated stratified healthcare therapies by targeting particular driver mutations in various genes, e.g. BRAF inhibitors like vemurafenib for patients with BRAF V600E mutated tumors 3,4 . In combination with new mitogen-activated protein kinase kinase (MAP2K, MEK, MAPKK) inhibitors such as cobimetinib 5 life expectancy can be extended to about one year 6 with fewer side effects than the standard chemotherapeutic drug dacarbazine. The current gold standard for mutation screening in malignant tumors uses realtime polymerase chain reaction (PCR) and sequencing methods for DNA extracted from biopsies. Our method neither needs PCR, nor labelling, nor sequencing. PCR protocols can be error-prone with false positives as a particular hazard. Artifacts complicate protocols 7 and extend processing time. We use an array of nanomechanical microcantilevers for surface stress sensing based on atomic force microscopy 8 to analyze DNA/DNA hybridization 9-12 . The technique was further adapted to reveal antigen/antibody 13,14 , transcription factor/DNA interactions 15 and effects of antibiotics on bacteria 16 . The platform also proved applicability to study transcriptional 3 activity of genes 17,18 and is able to characterize function of transmembrane protein activity 19 .Here, we report on the detection of the BRAF V600E mutation present in a subset of 50-60% malignant me...